Home » Newsletters » BioWorld Science

BioWorld Science

March 15, 2021

View Archived Issues

Immune response research shows GM-CSF plays role in COVID-19 severity

Many elite controllers at HIV's ground zero

Targeting membrane protein starves pancreatic tumors

Henlius initiates dosing in phase II/III study of HLX-10 plus bevacizumab in first-line mCRC

Chinese researchers disclose SCN10A blockers

Hunan Warrant Pharmaceuticals patents Bcr-Abl1 and/or BTK inhibitors

Inflazome synthesizes new NLRP3 inflammasome inhibitors

Galapagos presents TYK2 inhibitors

Successful completion of IND-enabling rodent toxicology studies with R-107

The Feinstein Institute for Medical Research divulges tetranectin-targeting antibodies

GSK-3640254 demonstrates safety and dose-antiviral response relationship in phase IIa trial

ALG-097111: targeting 3CLpro for treating SARS-CoV-2

E-2027 improves cognitive function in mouse model of AD

Inhibrx identifies MTD of INBRX-105 in first-in-human study in solid tumors

I-SPY COVID trial drops apremilast for futility

DARPins as promising mutation-resistant antivirals for potential SARS-CoV-2 treatment

Tilt advances phase I trial of TILT-123 in metastatic melanoma

New phase II trial investigates Tedopi with Keytruda for recurrent ovarian cancer

Phase III trial of Libtayo in advanced cervical cancer stopped early for favorable OS data

Helixmith initiates phase II study of Engensis in ALS

Improved delivery observed for ABL-301 in mouse models of PD

IFN-mediated NAD depletion by upregulation of PARP9/10/14 sensitizes PDAC cells to NAMPT inhibitors

NSD3 drives oncogenesis in LUSC, but may sensitize these tumors to bromodomain inhibition

Boehringer Ingelheim ends phase II trial of BI-764198 for COVID-19-related ARDS

SiteOne initiates phase I study of ST-2427 in healthy volunteers

Rubius reports initial data from phase I/II study of RTX-240 in advanced solid tumors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...